Cargando…

Data Mining of the Public Version of the FDA Adverse Event Reporting System

The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS, formerly AERS) is a database that contains information on adverse event and medication error reports submitted to the FDA. Besides those from manufacturers, reports can be submitted from health care professionals and th...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakaeda, Toshiyuki, Tamon, Akiko, Kadoyama, Kaori, Okuno, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689877/
https://www.ncbi.nlm.nih.gov/pubmed/23794943
http://dx.doi.org/10.7150/ijms.6048
_version_ 1782274324055457792
author Sakaeda, Toshiyuki
Tamon, Akiko
Kadoyama, Kaori
Okuno, Yasushi
author_facet Sakaeda, Toshiyuki
Tamon, Akiko
Kadoyama, Kaori
Okuno, Yasushi
author_sort Sakaeda, Toshiyuki
collection PubMed
description The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS, formerly AERS) is a database that contains information on adverse event and medication error reports submitted to the FDA. Besides those from manufacturers, reports can be submitted from health care professionals and the public. The original system was started in 1969, but since the last major revision in 1997, reporting has markedly increased. Data mining algorithms have been developed for the quantitative detection of signals from such a large database, where a signal means a statistical association between a drug and an adverse event or a drug-associated adverse event, including the proportional reporting ratio (PRR), the reporting odds ratio (ROR), the information component (IC), and the empirical Bayes geometric mean (EBGM). A survey of our previous reports suggested that the ROR provided the highest number of signals, and the EBGM the lowest. Additionally, an analysis of warfarin-, aspirin- and clopidogrel-associated adverse events suggested that all EBGM-based signals were included in the PRR-based signals, and also in the IC- or ROR-based ones, and that the PRR- and IC-based signals were in the ROR-based ones. In this article, the latest information on this area is summarized for future pharmacoepidemiological studies and/or pharmacovigilance analyses.
format Online
Article
Text
id pubmed-3689877
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-36898772013-06-23 Data Mining of the Public Version of the FDA Adverse Event Reporting System Sakaeda, Toshiyuki Tamon, Akiko Kadoyama, Kaori Okuno, Yasushi Int J Med Sci Review The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS, formerly AERS) is a database that contains information on adverse event and medication error reports submitted to the FDA. Besides those from manufacturers, reports can be submitted from health care professionals and the public. The original system was started in 1969, but since the last major revision in 1997, reporting has markedly increased. Data mining algorithms have been developed for the quantitative detection of signals from such a large database, where a signal means a statistical association between a drug and an adverse event or a drug-associated adverse event, including the proportional reporting ratio (PRR), the reporting odds ratio (ROR), the information component (IC), and the empirical Bayes geometric mean (EBGM). A survey of our previous reports suggested that the ROR provided the highest number of signals, and the EBGM the lowest. Additionally, an analysis of warfarin-, aspirin- and clopidogrel-associated adverse events suggested that all EBGM-based signals were included in the PRR-based signals, and also in the IC- or ROR-based ones, and that the PRR- and IC-based signals were in the ROR-based ones. In this article, the latest information on this area is summarized for future pharmacoepidemiological studies and/or pharmacovigilance analyses. Ivyspring International Publisher 2013-04-25 /pmc/articles/PMC3689877/ /pubmed/23794943 http://dx.doi.org/10.7150/ijms.6048 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.
spellingShingle Review
Sakaeda, Toshiyuki
Tamon, Akiko
Kadoyama, Kaori
Okuno, Yasushi
Data Mining of the Public Version of the FDA Adverse Event Reporting System
title Data Mining of the Public Version of the FDA Adverse Event Reporting System
title_full Data Mining of the Public Version of the FDA Adverse Event Reporting System
title_fullStr Data Mining of the Public Version of the FDA Adverse Event Reporting System
title_full_unstemmed Data Mining of the Public Version of the FDA Adverse Event Reporting System
title_short Data Mining of the Public Version of the FDA Adverse Event Reporting System
title_sort data mining of the public version of the fda adverse event reporting system
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689877/
https://www.ncbi.nlm.nih.gov/pubmed/23794943
http://dx.doi.org/10.7150/ijms.6048
work_keys_str_mv AT sakaedatoshiyuki dataminingofthepublicversionofthefdaadverseeventreportingsystem
AT tamonakiko dataminingofthepublicversionofthefdaadverseeventreportingsystem
AT kadoyamakaori dataminingofthepublicversionofthefdaadverseeventreportingsystem
AT okunoyasushi dataminingofthepublicversionofthefdaadverseeventreportingsystem